Stock CRBP CORBUS PHARMACEUTICALS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Corbus Pharmaceuticals Holdings, Inc.

Equities

CRBP

US21833P3010

Real-time Estimate Cboe BZX
Other stock markets
 12:13:37 2024-04-19 pm EDT 		5-day change 1st Jan Change
38.46 USD +5.27% Intraday chart for Corbus Pharmaceuticals Holdings, Inc. -6.99% +529.06%
Apr. 02 Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC CI
Mar. 13 Corbus Pharmaceuticals Files Mixed Shelf MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
AQ
Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
CI
Corbus Pharmaceuticals Files Mixed Shelf
MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $58 From $51, Maintains Outperform Rating
MT
Health Care Climbs on Risk Appetite -- Health Care Roundup
DJ
Corbus Pharmaceuticals: Q4 Earnings Snapshot
AQ
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
AQ
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
North American Morning Briefing : Inflation Data -2-
DJ
North American Morning Briefing : Powell Still in -2-
DJ
Jefferies Upgrades Corbus Pharmaceuticals Holdings to Buy From Hold
MT
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
AQ
Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer
CI
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
AQ
Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024
CI
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
AQ
Corbus Pharmaceuticals Closes $94.5 Million Public Offering
MT
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
AQ
Corbus Pharmaceuticals Announces Pricing of Public Offering
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRBP Stock
  4. News Corbus Pharmaceuticals Holdings, Inc.